Skip to main
CVS

CVS Health (CVS) Stock Forecast & Price Target

CVS Health (CVS) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 61%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CVS Health is poised for strong growth in the coming years, driven by its diverse set of healthcare services including retail pharmacy operations, pharmacy benefit management, and health insurance. The recent acquisition of Oak Street Health has added primary care services to the mix, further enhancing synergies with existing business lines. Moreover, CVS's strong financial position, with improved cash flow and ongoing financial flexibility, positions the company well for future growth opportunities. Overall, the company's robust clinical capabilities and focus on patient cost, quality, and accessibility make it a solid investment opportunity.

Bears say

CVS Health is facing significant challenges in its retail pharmacy business due to regulatory price reductions, generic introductions, and reimbursement pressures. These factors are impacting the company's financial performance, with a decline in segment AOI and lower revenue growth. While management has raised guidance for the P&CW segment, the company is still at risk of membership losses, regulatory scrutiny, and increased competition in the retail market. Despite potential improvements in areas such as specialty healthcare and margin improvement within the healthcare delivery segment, overall profitability may continue to be a drag on the company in the near term.

CVS Health (CVS) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 61% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CVS Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CVS Health (CVS) Forecast

Analysts have given CVS Health (CVS) a Buy based on their latest research and market trends.

According to 18 analysts, CVS Health (CVS) has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CVS Health (CVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.